Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Recurso digital |
| Kieli: | |
| Julkaistu: |
Zenodo
2026
|
| Aiheet: | |
| Linkit: | https://doi.org/10.5281/zenodo.20350086 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Sisällysluettelo:
- <p class="MsoNormal"><span>Poor aqueous solubility is one of the major challenges in oral drug delivery, particularly for Biopharmaceutical Classification System (BCS) Class II drugs characterized by low solubility and high permeability. Limited solubility results in poor dissolution rate and reduced oral bioavailability, thereby affecting therapeutic efficacy. Nanosuspension technology has emerged as an effective strategy to enhance dissolution, saturation solubility, and bioavailability of poorly water-soluble drugs. The present study aimed to design, develop, and evaluate nanosuspensions of a poorly water-soluble BCS Class II drug using high-speed homogenization followed by ultrasonication technique. Various stabilizers such as polyvinyl alcohol (PVA), poloxamer 188, and hydroxypropyl methylcellulose (HPMC) were employed for stabilization of nanosuspensions. The prepared formulations were evaluated for particle size, polydispersity index, zeta potential, drug content, saturation solubility, dissolution behavior, morphology, and stability studies. The optimized nanosuspension demonstrated nanosized particles, enhanced dissolution rate, improved saturation solubility, and superior stability compared with pure drug suspension. The study confirmed that nanosuspension technology is a promising approach for improving oral bioavailability of poorly soluble BCS Class II drugs.</span></p>